p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis

Cancer Cell

Volumn 3, Issue 4, 2003, Pages 387-402

  Bergamaschi, Daniele ^a   Gasco, Milena ^b   Hiller, Louise ^c   Sullivan, Alexandra ^a   Syed, Nelofer ^a   Trigiante, Giuseppe ^a   Yulug, Isik ^d   Merlano, Marco ^b   Numico, Gianmauro ^b   Comino, Alberto ^b   Attard, Marlene ^a   Reelfs, Olivier ^a   Gusterson, Barry ^e   Bell, Alexandra K ^e   Heath, Victoria ^e   Tavassoli, Mahvash ^f   Farrell, Paul J ^a   Smith, Paul ^g   Lu, Xin ^a   Crook, Tim ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b S CROCE E CARLE HOSPITAL   (Italy)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d BILKENT UNIVERSITY   (Turkey)

^e UNIVERSITY OF GLASGOW   (United Kingdom)

^f KING'S COLLEGE LONDON   (United Kingdom)

^g BRUNEL UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARGININE; CISPLATIN; MUTANT PROTEIN; PROLINE; PROTEIN P53; PROTEIN P73; DNA BINDING PROTEIN; NUCLEAR PROTEIN; SMALL INTERFERING RNA; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ADVANCED CANCER; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CODON; CONTROLLED STUDY; GENETIC CODE; GENETIC POLYMORPHISM; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; ADULT; AGED; CELL CULTURE; DRUG RESISTANCE; DRUG THERAPY; FEMALE; GENETICS; HEAD AND NECK TUMOR; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; METABOLISM; MIDDLE AGED; MUTATION; PHYSIOLOGY; PLASMID; PROGNOSIS; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR SUPPRESSOR GENE;

ADULT; AGED; APOPTOSIS; CARCINOMA, SQUAMOUS CELL; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; DRUG THERAPY; FEMALE; GENES, P53; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; NUCLEAR PROTEINS; PLASMIDS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 10744230945     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(03)00079-5     Document Type: Article

References (46)

1. Agami R., Blandino G., Oren M., Shaul Y. Interaction of c-Abl and p73alpha and their collaboration to induce apoptosis. Nature. 399:1999;809-813.
2. Alsner J., Sorensen S.B., Overgaard J. TP53 mutation is related to poor prognosis after radiotherapy, but not surgery, in squamous cell carcinoma of the head and neck. Radiother. Oncol. 59:2001;179-185.
3. Blandino G., Levine A.J., Oren M. Mutant p53 gain of function. differential effects of different p53 mutants on resistance of cultured cells to chemotherapy Oncogene. 18:1999;477-485.
4. Brooks L.A., Tidy J.A., Gusterson B., Hiller L., O'Nions J., Gasco M., Marin M.C., Farrell P.J., Kaelin W.G. Jr., Crook T. Preferential retention of codon 72 arginine p53 in squamous cell carcinomas of the vulva occurs in cancers positive and negative for human papillomavirus. Cancer Res. 60:2000;6875-6877.
5. Brooks L.A., Sullivan A., O'Nions J., Bell A., Dunne B., Tidy J.A., Evans D.J., Osin P., Vousden K.H., Gusterson B.et al. E7 proteins from oncogenic human papillomavirus types transactivate p73. role in cervical intraepithelial neoplasia Br. J. Cancer. 86:2002;263-268.
6. Cabelguenne A., Blons H., de Waziers I., Carnot F., Houllier A.M., Soussi T., Brasnu D., Laccourreye O., Laurent-Puig P. p53 alterations predict tumor response to neoadjuvant chemotherapy in head and neck squamous cell carcinoma. a prospective series J. Clin. Oncol. 18:2000;1465-1473.
7. Cai Y.C., Yang G.Y., Nie Y., Wang L.D., Zhao X., Song Y.L., Seril D.N., Liao J., Xing E.P., Yang C.S. Molecular alterations of p73 in human esophageal squamous cell carcinomas. loss of heterozygosity occurs frequently; loss of imprinting and elevation of p73 expression may be related to defective p53 Carcinogenesis. 21:2000;683-689.
8. Costanzo A., Merlo P., Pediconi N., Fulco M., Sartorelli V., Cole P.A., Fontemaggi G., Fanciulli M., Schiltz L., Blandino G.et al. DNA damage-dependent acetylation of p73 dictates the selective activation of apoptotic target genes. Mol. Cell. 9:2002;175-186.
9. Cox D.R. Regression models and life tables. J. R. Stat. Soc. Ser. B. 34:1972;187-220.
10. Crook T., Marston N.J., Sara E.A., Vousden K.H. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell. 79:1994;817-827.
11. De Laurenzi V., Costanzo A., Barcaroli D., Terrinoni A., Falco M., Annicchiarico-Petruzzelli M., Levrero M., Melino G. Two new p73 splice variants, gamma and delta, with different transcriptional activity. J. Exp. Med. 188:1998;1763-1768.
12. Di Como C.J., Gaiddon C., Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol. Cell. Biol. 19:1999;1438-1449.
13. Elbashir S.M., Harborth J., Lendeckel W., Yalcin A., Weber K., Tuschl T. Duplexes of 21-nucleotide RNAs mediate RNA intereference in cultured mammalian cells. Nature. 411:2001;494-498.
14. Fillippovich I., Sorokina N., Gatei M., Haupt Y., Hobson K., Moallem E., Spring K., Mould M., McGuckin M.A., Lavin M.F., Khanna K.K. Transactivation- deficient p73alpha (p73Deltaexon2) inhibits apoptosis and competes with p53. Oncogene. 20:2001;514-522.
15. Fouret P., Temam S., Charlotte F., Lacau-St-Guilly J. Tumour stage, node stage, p53 gene status and bcl-2 protein expression as predictors of tumour response to platin-fluouracil chemotherapy in patients with squamous-cell carcinoma of the head and neck. Br. J. Cancer. 87:2002;1390-1395.
16. Furihata M., Takeuchi T., Matsumoto M., Kurabayashi A., Ohtsuki Y., Terao N., Kuwahara M., Shuin T. p53 mutation arising in Arg72 allele in the tumorigenesis and development of carcinoma of the urinary tract. Clin. Cancer Res. 8:2002;1192-1195.
17. Gaiddon C., Lokshin M., Ahn J., Zhang T., Prives C.A. A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain. Mol. Cell. Biol. 21:2001;1874-1887.
18. Gallo O., Chiarelli I., Boddi V., Boccioloni C., Bruschini L., Porfirio B. Cumulative prognostic value of p53 mutations and bcl-2 protein expression in head-and-neck cancer treated by radiotherapy. Int. J. Cancer. 84:1999;573-579.
19. Gong J.G., Costanzo A., Yang H.-Q., Melino G., Kaelin W.G. Jr., Levrero M., Wang J.Y.J. The tyrosine kinase c-Abl regulates p73 in apoptotic response to cisplatin-induced DNA damage. Nature. 399:1999;806-809.
20. Irwin M., Marin M.C., Phillips A.C., Seelan R.S., Smith D.I., Liu W., Flores E.R., Tsai K.Y., Jacks T., Vousden K.H., Kaelin W.G. Jr. Role for the p53 homologue p73 in E2F-1-induced apoptosis. Nature. 407:2000;645-648.
21. Irwin M.S., Kondo K., Marin M.C., Hahn W.C., Kaelin W.G. Jr. Chemosensitivity linked to p73 function. Cancer Cell. 3:2003;403-410. this issue
22. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis. a link between cancer genetics and chemotherapy Cell. 108:2002;153-164.
23. Kaeser M.D., Iggo R.D. Chromatin immunoprecipitation analysis fails to support the latency model for regulation of p53 DNA binding activity in vivo. Proc. Natl. Acad. Sci. USA. 99:2002;95-100.
24. Kaghad M., Bonnet H., Yang A., Creancier L., Biscan J.C., Valent A., Minty A., Chalon P., Lelias J.M., Dumont X.et al. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell. 90:1997;809-819.
25. Kaplan E.L., Meier P. Non parametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457.
26. Koch W.M., Brennan J.A., Zahurak M., Goodman S.N., Westra W.H., Schwab D., Yoo G.H., Lee D.J., Forastiere A.A., Sidransky D. p53 mutation and locoregional treatment failure in head and neck squamous cell carcinoma. J. Natl. Cancer Inst. 88:1996;1580-1586.
27. Li R., Sutphin P.D., Schwartz D., Matas D., Almog N., Wolkowicz R., Goldfinger N., Pei H., Prokocimer M., Rotter V. Mutant p53 protein expression interferes with p53-independent apoptotic pathways. Oncogene. 16:1998;3269-3277.
28. Lowe S.W., Ruley H.E., Jacks T., Housman D.E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell. 75:1993;957-967.
29. Lowe S.W., Bodis S., McClatchey A., Remington L., Ruley H.E., Fisher E.D., Housman D.E., Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science. 266:1994;807-810.
30. Marin M.C., Jost C.A., Brooks L.A., Irwin M.S., O'Nions J., Tidy J.A., James N., McGregor J.M., Harwood C.A., Yulug I.G.et al. A common polymorphism acts as intragenic modifier of mutant p53 behaviour. Nat. Genet. 25:2000;47-54.
31. Peto R., Pike M.C., Armitage P., Breslow N.E., Cox D.R., Howard S.V., Mantel N., McPherson K., Peto J., Smith P.G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br. J. Cancer. 35:1977;1-39.
32. Riou G., Barrois M., Prost S., Terrier M.J., Theodore C., Levine A.J. The p53 and mdm-2 genes in human testicular germ-cell tumors. Mol. Carcinog. 12:1995;124-131.
33. Schmitt C.A., Fridman J.S., Yang M., Baranov E., Hoffman R.M., Lowe S.W. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 1:2002;289-298.
34. Soussi T., Béroud C. Assessing TP53 status in human tumours to evaluate clinical outcome. Nat. Rev. Cancer. 1:2001;233-239.
35. Stiewe T., Putzer B.M. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat. Genet. 26:2000;464-469.
36. Stiewe T., Zimmermann S., Frilling A., Esche H., Putzer M. Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res. 62:2002;3598-3602.
37. Strano S., Munarriz E., Rossi M., Cristofanelli B., Shaul Y., Castagnoli L., Levine A.J., Sacchi A., Cesareni G., Oren M., Blandino G. Physical and functional interaction between p53 mutants and different isoforms of p73. J. Biol. Chem. 275:2000;29503-29512.
38. Strano S., Fontemaggi G., Costanzo A., Rizzo M.G., Monti O., Baccarini A., Del Sal G., Levrero M., Sacchi A., Oren M., Blandino G. Physical interaction with human tumor-derived p53 mutants inhibits p63 activities. J. Biol. Chem. 277:2002;18817-18826.
39. Tada M., Furuuchi K., Kaneda M., Matsumoto J., Takahashi M., Hirai A., Mitsumoto Y., Iggo R.D., Moriuchi T. Inactivate the remaining p53 allele or the alternate p73? Preferential selection of the Arg72 polymorphism in cancers with recessive p53 mutants but not transdominant mutants. Carcinogenesis. 22:2001;515-517.
40. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature. 408:2000;307-310.
41. Vousden K.H., Lu X. Live or let die. the cell's response to p53 Nat. Rev. Cancer. 2:2002;594-604.
42. Yamazaki Y., Chiba I., Hirai A., Sugiura C., Notani K., Kashiwazaki H., Tei K., Totsuka Y., Fukuda H. Specific p53 mutations predict poor prognosis in oral squamous cell carcinoma. Oral Oncol. 39:2003;163-169.
43. Yuan Z.M., Shioya H., Ishiko T., Sun X., Gu J., Huang Y.Y., Lu H., Kharbanda S., Weichselbaum R., Kufe D. p73 is regulated by tyrosine kinase c-Abl in the apoptotic response to DNA damage. Nature. 399:1999;814-817.
44. Zaika A.I., Kovalev S., Marchenko N.D., Moll U.M. Overexpression of the wild type p73 gene in breast cancer tissues and cell lines. Cancer Res. 59:1999;3257-3263.
45. Zaika A., Irwin M., Sansome C., Moll U.M. Oncogenes induce and activate endogenous p73 protein. J. Biol. Chem. 276:2001;11310-11316.
46. Zaika A.I., Slade N., Erster S.H., Sansome C., Joseph T.W., Pearl M., Chalas E., Moll U.M. DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J. Exp. Med. 196:2002;765-780.